A paper that has recently been published looks into the safety and efficacy of treating patients with active rheumatoid arthritis with umbilical cord mesenchymal stem cells (UC-MSCs).
172 patients were divided into 2 groups. One group received disease-modifying drugs plus medium without UC-MSCs and the other received disease-modifying drugs plus UC-MSCs. The trial indicated that treatment with disease-modifying drugs plus UC-MSCs may provide safe, significant and persistent clinical benefits for patients with active rheumatoid arthritis.
For more on this article click here
BSc (Hons) Microbiology
Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.